4.170USD-1.18%Mkt Cap: 245.42M USDP/E: —Last update: 2026-05-26
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the Uni…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap245.42M USD
Enterprise Value102.61M USD
Revenue (TTM)28.22M USD
Gross Profit-53.88M USD
Net Income (TTM)-74.28M USD
Revenue/Share0.4370 USD
Last Price4.170 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees106
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.48
PEG—
EV/EBITDA-1.31
EV/Revenue3.64
P/S8.65
P/B-3.20
EPS (TTM)-1.17
EPS (Forward)-0.93
52W Range
3.27024% of range6.950
52W High6.950 USD
52W Low3.270 USD
Profitability
Gross Margin-190.88%
Oper. Margin-660.33%
EBITDA Margin-276.45%
Profit Margin-240.33%
ROE68.46%
ROA-37.50%
Growth
Revenue Growth-45.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-86.10M USD
CapEx (TTM)50.00K USD
FCF Margin-130.83%
FCF Yield-15.05%
Net Debt-141.64M USD
Net Debt/EBITDA1.82
Balance Sheet
Debt/Equity-0.38
Current Ratio2.92
Quick Ratio2.85
Book Value/Sh-1.3010 USD
Cash/Share3.128 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)11.44 USD
Target Range9.000 USD – 14.00 USD
# Analysts9
Ownership
Shares Out.58.71M
Float27.41M
Insiders17.94%
Institutions76.49%
Short Interest
Short Ratio10.6d
Short % Float4.24%
Short % Out.2.31%
Shares Short1.36M
Short (prev mo.)1.33M
Technical
SMA 504.733 (-11.9%)
SMA 2004.964 (-16.0%)
Beta2.97
S&P 52W Chg28.31%
Avg Vol (30d)136.31K
Avg Vol (10d)176.38K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—